146 related articles for article (PubMed ID: 10494994)
1. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats.
Malpass A; White JM; Irvine RJ; Somogyi AA; Bochner F
Pharmacol Biochem Behav; 1999 Sep; 64(1):29-34. PubMed ID: 10494994
[TBL] [Abstract][Full Text] [Related]
2. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
Colado MI; Williams JL; Green AR
Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557
[TBL] [Abstract][Full Text] [Related]
3. Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
Fonsart J; Menet MC; Declèves X; Galons H; Crété D; Debray M; Scherrmann JM; Noble F
Toxicol Appl Pharmacol; 2008 Jul; 230(1):117-25. PubMed ID: 18358511
[TBL] [Abstract][Full Text] [Related]
4. Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression.
Schulz-Utermoehl T; Bennett AJ; Ellis SW; Tucker GT; Boobis AR; Edwards RJ
Pharmacogenetics; 1999 Jun; 9(3):357-66. PubMed ID: 10471068
[TBL] [Abstract][Full Text] [Related]
5. Increased effects of 3,4-methylenedioxymethamphetamine (ecstasy) in a rat model of depression.
Jaehne EJ; Majumder I; Salem A; Irvine RJ
Addict Biol; 2011 Jan; 16(1):7-19. PubMed ID: 20192951
[TBL] [Abstract][Full Text] [Related]
6. A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long-term defect in thermoregulation.
Mechan AO; O'Shea E; Elliott JM; Colado MI; Green AR
Psychopharmacology (Berl); 2001 Jun; 155(4):413-8. PubMed ID: 11441431
[TBL] [Abstract][Full Text] [Related]
7. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro.
Ramamoorthy Y; Yu AM; Suh N; Haining RL; Tyndale RF; Sellers EM
Biochem Pharmacol; 2002 Jun; 63(12):2111-9. PubMed ID: 12110370
[TBL] [Abstract][Full Text] [Related]
8. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion.
Chu T; Kumagai Y; DiStefano EW; Cho AK
Biochem Pharmacol; 1996 Mar; 51(6):789-96. PubMed ID: 8602874
[TBL] [Abstract][Full Text] [Related]
9. Involvement of mitochondrial/lysosomal toxic cross-talk in ecstasy induced liver toxicity under hyperthermic condition.
Pourahmad J; Eskandari MR; Nosrati M; Kobarfard F; Khajeamiri AR
Eur J Pharmacol; 2010 Sep; 643(2-3):162-9. PubMed ID: 20599925
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2.
Yamamoto Y; Tasaki T; Nakamura A; Iwata H; Kazusaka A; Gonzalez FJ; Fujita S
Pharmacogenetics; 1998 Feb; 8(1):73-82. PubMed ID: 9511184
[TBL] [Abstract][Full Text] [Related]
11. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
McNamara R; Kerans A; O'Neill B; Harkin A
Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
[TBL] [Abstract][Full Text] [Related]
12. Genetic differences in spatial learning between Dark Agouti and Sprague-Dawley strains: possible correlation with the CYP2D2 polymorphism in rats treated neonatally with methamphetamine.
Vorhees CV; Morford LL; Inman SL; Reed TM; Schilling MA; Cappon GD; Moran MS; Nebert DW
Pharmacogenetics; 1999 Apr; 9(2):171-81. PubMed ID: 10376764
[TBL] [Abstract][Full Text] [Related]
13. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
Yang J; Jamei M; Heydari A; Yeo KR; de la Torre R; Farré M; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):842-9. PubMed ID: 16714321
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Barham HM; Lennard MS; Tucker GT
Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
[TBL] [Abstract][Full Text] [Related]
16. Strain differences in rat brain and liver sigma binding: lack of cytochrome P450-2D1 involvement.
Jewell A; Wedlund P; Dwoskin L
Eur J Pharmacol; 1993 Oct; 243(3):249-54. PubMed ID: 8276077
[TBL] [Abstract][Full Text] [Related]
17. Atypical development of behavioural sensitization to 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') in adolescent rats and its expression in adulthood: role of the MDMA chirality.
von Ameln N; von Ameln-Mayerhofer A
Addict Biol; 2010 Jan; 15(1):35-44. PubMed ID: 20002021
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy).
Easton N; Fry J; O'Shea E; Watkins A; Kingston S; Marsden CA
Brain Res; 2003 Oct; 987(2):144-54. PubMed ID: 14499958
[TBL] [Abstract][Full Text] [Related]
19. Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature.
Carvalho M; Carvalho F; Remião F; de Lourdes Pereira M; Pires-das-Neves R; de Lourdes Bastos M
Arch Toxicol; 2002 Apr; 76(3):166-72. PubMed ID: 11967622
[TBL] [Abstract][Full Text] [Related]
20. CYP2D1 polymorphism in methamphetamine-treated rats: genetic differences in neonatal mortality and effects on spatial learning and acoustic startle.
Vorhees CV; Reed TM; Schilling MA; Fisher JE; Moran MS; Cappon GD; Nebert DW
Neurotoxicol Teratol; 1998; 20(3):265-73. PubMed ID: 9638684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
